Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

(2022) Wilfredo F. Garcia-Beltran et al.   CELL

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

(2022) Sam Afkhami et al.   CELL

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

(2022) Delphine Planas et al.   NATURE

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

(2022) Jingxin Li et al.   NATURE MEDICINE

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques

(2022) Fang Xu et al.   Emerging Microbes & Infections

T resident helper cells promote humoral responses in the lung

(2021) Nivedya Swarnalekha et al.   Science Immunology

Emergence of a Novel SARS-CoV-2 Variant in Southern California

(2021) Wenjuan Zhang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

SARS‐CoV‐2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two‐dose CoronaVac vaccine regimen

(2021) Ali Umit Keskin et al.   JOURNAL OF MEDICAL VIROLOGY

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

(2021) Shipo Wu et al.   LANCET INFECTIOUS DISEASES

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

(2021) Johan Normark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

(2021) Arabella S V Stuart et al.   LANCET

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

(2021) Szu-Min Hsieh et al.   Lancet Respiratory Medicine

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

(2020) Hui Wang et al.   CELL

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

T cell immunity to SARS-CoV-2 following natural infection and vaccination

(2020) Anthony T. DiPiazza et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS